Organon & Co (OGN)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $3.65B
Last updated: Nov 17, 2026 at 4:20 PM ET
Organon & Co (OGN) Statistics
Organon (OGN) has a market cap of $3.65B and an enterprise value of $10.75B. Its net debt of $7.10B equals 194.47% of its market cap.
Total Valuation
Enterprise value is 194.47% above the market cap, as debt exceeds cash.
| Market Cap | $3.65B |
|---|---|
| Enterprise Value | $10.75B |
| Latest price (Nov 17, 2026) | $13.90 |
Key Dates
The next earnings report is expected on Feb 10, 2027, covering the quarter ending Dec 31, 2026. The last ex-dividend date was Nov 9, 2026.
| Next Earnings Date | Feb 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 30, 2026 |
| Last Ex-Dividend Date | Nov 9, 2026 |
| Next Payment Date | Dec 10, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 0.6x and 3.1x. Its year-end P/E ranged from 2.0x to 5.6x from 2021 to 2025.
| P/E Ratio | 4.6x |
|---|---|
| Forward P/E | 4.0x |
| P/S Ratio | 0.6x |
| Forward P/S | 0.6x |
| P/B Ratio | 3.1x |
| P/FCF Ratio | 5.4x |
| P/OCF Ratio | 4.3x |
Enterprise Valuation
Counting debt and cash, the company is valued at 8.4x EBITDA and 15.9x free cash flow.
| EV / Earnings | 50.5x |
|---|---|
| EV / Sales | 1.8x |
| EV / EBITDA | 8.4x |
| EV / EBIT | 11.5x |
| EV / FCF | 15.9x |
Price Statistics
The stock is up 85.86% over 52 weeks and trades 1.09% above its 50-day average.
| Beta (1Y) | 0.57 |
|---|---|
| 52-Week Change | +85.86% |
| 1-Month Change | +1.24% |
| 3-Month Change | +1.38% |
| 6-Month Change | +3.73% |
| 5-Year Change | -62.34% |
| Total Return (1Y) | +87.20% |
| Total Return (3Y CAGR) | +10.37% |
| Total Return (5Y CAGR) | -11.77% |
| Return vs SPY (1Y) | +69.96% |
| Max Drawdown (1Y) | -41.54% |
| Max Drawdown (3Y) | -74.12% |
| Sharpe Ratio (1Y) | 1.11 |
| Correlation with SPY (1Y) | 0.15 |
| 50-Day Average | $13.75 |
| 200-Day Average | $11.78 |
| 52-Week Range | $5.67 to $13.91 |
| RSI (14 Days) | 69.2 |
| Average Volume (20 Days) | 2.75M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.02x current liabilities, and total debt is 7.17x shareholder equity.
| Current Ratio | 2.02x |
|---|---|
| Quick Ratio | 1.51x |
| Debt / Equity | 7.17x |
| Debt / EBITDA | 6.68x |
| Debt / FCF | 12.67x |
| Interest Coverage | 2.16x |
Returns and Efficiency
Return on invested capital is 6.25% over the last 12 months, against a 5-year average of 14.17%.
| Return on Equity (ROE) | 17.85% |
|---|---|
| Return on Assets (ROA) | 1.59% |
| Return on Invested Capital (ROIC) | 6.25% |
| Return on Capital Employed (ROCE) | 8.72% |
| ROA (5Y Average) | 7.51% |
| ROIC (5Y Average) | 14.17% |
| Asset Turnover | 0.45x |
| Inventory Turnover | 2.11x |
| Receivables Turnover | 4.10x |
| Cash Conversion Cycle | 132 days |
Taxes
Income tax took 57.65% of pretax income over the last 12 months.
| Income Tax (TTM) | $290.00M |
|---|---|
| Effective Tax Rate | 57.65% |
Scores
OGN has an Altman Z-Score of 1.27, in the distress zone below 1.81, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 1.27 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $6.10B over the last 12 months is down 3.21% from the 12 months before.
| Revenue | $6.10B |
|---|---|
| Revenue Growth (YoY) | -3.21% |
| Gross Profit | $3.24B |
| Operating Income | $831.00M |
| Pretax Income | $503.00M |
| Net Income | $213.00M |
| EBITDA | $1.28B |
| EBIT | $937.00M |
| Reported EPS (TTM) | $3.02 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 8.88% of the $13.40B in total assets.
| Cash and Equivalents | $1.46B |
|---|---|
| Total Debt | $8.55B |
| Net Debt | $7.10B |
| Net Debt Per Share | $27.03 |
| Working Capital | $2.72B |
| Shareholder Equity | $1.19B |
| Book Value Per Share | $4.54 |
| Tangible Book Value | -$4.03B |
| Total Assets | $13.40B |
| Total Liabilities | $12.21B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $168.00M of capital spending, operating cash flow left $675.00M of free cash flow.
| Operating Cash Flow | $843.00M |
|---|---|
| Capital Expenditures | $168.00M |
| Free Cash Flow | $675.00M |
| FCF Per Share | $2.57 |
| Depreciation and Amortization | $344.00M |
| Dividends Paid | $20.00M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 13.63%, against a 5-year average of 21.72%.
| Gross Margin | 53.12% |
|---|---|
| Operating Margin | 13.63% |
| Pretax Margin | 8.25% |
| Net Margin | 3.49% |
| EBITDA Margin | 21.00% |
| EBIT Margin | 15.36% |
| FCF Margin | 11.07% |
| Gross Margin (5Y Average) | 59.19% |
| Operating Margin (5Y Average) | 21.72% |
| Net Margin (5Y Average) | 13.82% |
Growth
Revenue grew 0.23% a year over 3 years, and EPS fell 10.06% a year.
| Revenue Growth (3Y CAGR) | +0.23% |
|---|---|
| Revenue Growth (5Y CAGR) | -0.99% |
| EPS Growth (3Y CAGR) | -10.06% |
| FCF Growth (3Y CAGR) | -6.68% |
| FCF Growth (5Y CAGR) | -23.32% |
| Operating Income Growth (3Y CAGR) | -19.34% |
Dividends and Yields
OGN pays out 3.12% of earnings as dividends.
| Dividend Per Share (Annual) | $0.08 |
|---|---|
| Dividend Yield | 0.58% |
| Payment Schedule | Quarterly |
| Dividend Growth (3Y CAGR) | -62.30% |
| Payout Ratio | 3.12% |
| FCF Payout Ratio | 2.96% |
| Earnings Yield | 21.74% |
| FCF Yield | 18.49% |
| Shareholder Yield | 0.55% |
Peer Position
Against 8 similar companies, OGN has the lowest P/E and the 6th highest ROIC.
P/E RatioPeer median 27.3x
P/S RatioPeer median 4.5x
ROICPeer median 7.28%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +5.62%
Dividend YieldPeer median 0.00%
| P/E Ratio | 4.6x vs 27.3x median |
|---|---|
| P/S Ratio | 0.6x vs 4.5x median |
| ROIC | 6.25% vs 7.28% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -3.21% vs +5.62% median |
| Dividend Yield | 0.58% vs 0.00% median |
Analyst Forecast
Consensus estimates put revenue growth at 0.56% and EPS growth at -0.17% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +0.56% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | -0.17% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About OGN
What is OGN's market cap?
Organon has a market cap of $3.65B. Its enterprise value, which adds debt and subtracts cash, is $10.75B.
What is OGN's P/E ratio?
Organon has a trailing P/E ratio of 4.6x and a forward P/E of 4.0x.
How many shares of OGN are outstanding?
Organon has 262.62M shares outstanding. The count is up 1.02% from a year earlier.
Does OGN pay a dividend?
Yes. Organon pays $0.08 a share a year, a dividend yield of 0.58%.
How much debt does OGN have?
Organon has $8.55B of total debt and $1.46B of cash and equivalents, a net debt position of $7.10B.
OGN pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors